Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epithelial Malignancy and Junction-Modulating Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DSG2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DSG2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DSG2 Products |
| Gene Delivery | DSG2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer, sequence verified. |
View DSG2 Products |
| Benchmark Ab | Anti-DSG2 (Sequence of clinical-stage biosimilars) Recombinant positive control for binding and internalization assays. |
View DSG2 Products |
| Validator | DSG2 siRNA Set For knockdown verification in target-specificity assays. |
View DSG2 Products |
| Related Target A | DSG1 Critical homolog counter-screening target to prevent off-target pemphigus-like skin toxicity. |
View DSG1 Products |
| Related Target B | DSG3 Homolog screening target to ensure mucosal safety and absolute selectivity of DSG2 binders. |
View DSG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus DSG2 ortholog proteins available with >95% purity and verified molecular weight. |
| Subfamily counter-screening (DSG1/3/4) | Desmoglein family homolog panel proteins strictly verified by mass spectrometry and sequence-verified to guarantee zero cross-contamination. |
| Lack of Controls | Clinical-grade benchmark antibodies (biosimilars) included to establish solid baseline curves in SPR and FACS assays. |
| False Positives | Validated siRNA sets included to confirm target-specific phenotypic knockdown in cell-based assays. |
Live DSG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for DSG2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and junction-opening biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-selective epitopes to minimize cardiac and systemic epithelial toxicity."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Innovent Biologics, Academic Institutions | Gastric Cancer, Colorectal Cancer, Pancreatic Cancer | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc to validate antibody-antigen complex endocytosis) |
| Junction Opener / Enhancer | Nectin Therapeutics, Hoba Therapeutics | Solid Tumors (combination with mAb/Chemo) | Intercellular Junction Disruption Assay (Need Lentivirus for stable cell lines to evaluate barrier permeability) |
| CAR-T / Cell Therapy | Biotech Startups | DSG2-positive epithelial malignancies | Selectivity Assay (Need DSG1/3/4 recombinant proteins to rule out off-target reactivity against healthy skin/mucosa) |